Status:
SUSPENDED
Fluorescein Angiography With a Full-dose Versus a Half-dose of Intravenous Fluorescein
Lead Sponsor:
Kresge Eye Institute
Conditions:
Fluorescein Angiography
Eligibility:
All Genders
18-120 years
Phase:
PHASE4
Brief Summary
Fluorescein angiography is a common procedure used in ophthalmology to diagnose and monitor diseases of the eye. The standard dose of fluorescein dye used in fluorescein angiography is 500mg. It is co...
Detailed Description
Fluorescein angiography is a common procedure used in ophthalmology to diagnose and monitor diseases of the retinal and choroidal blood vessels. The most commonly seen adverse reactions to fluorescein...
Eligibility Criteria
Inclusion
- Adult patients scheduled for fluorescein angiography at Kresge Eye Institute.
Exclusion
- Patients with known major profusion defects on fluorescein angiography.
- Patients with prior adverse reactions to fluorescein angiography.
- Patients with significant photophobia as judged by the photographer.
- Patients with visually significant cataracts.
Key Trial Info
Start Date :
April 5 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2020
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT03244982
Start Date
April 5 2018
End Date
December 1 2020
Last Update
March 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kresge Eye Institute
Detroit, Michigan, United States, 48201